Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.
Moyle
G J
GJ
Kobler Clinic, Chelsea and Westminster Hospital, London, UK.
Gazzard
B G
BG
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D016049:Didanosine / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D009154:Mutation; D012194:RNA-Directed DNA Polymerase / Q000235:genetics*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D018119:Stavudine / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D018119:Stavudine; D012194:RNA-Directed DNA Polymerase; D016049:Didanosine